Literature DB >> 2173979

Mode of action of C-1027, a new macromolecular antitumor antibiotic with highly potent cytotoxicity, on human hepatoma BEL-7402 cells.

Y J Xu1, D D Li, Y S Zhen.   

Abstract

C-1027, a new macromolecular peptide antitumor antibiotic produced by a Streptomyces strain, was extremely cytotoxic to cultured cancer cells and markedly inhibited the growth of transplantable tumors in mice. As determined by tritium-labeled precursor-incorporation assay, C-1027 strongly inhibited DNA and RNA synthesis in hepatoma BEL-7402 cells without affecting protein synthesis. After incubation with the hepatoma cells for 4 h, IC50 values for [3H]-thymidine and [3H]-uridine incorporation were 0.00012 and 0.00032 microM, respectively. After 30 min incubation, C-1027 showed much stronger inhibition of [3H]-thymidine incorporation than did Adriamycin, mitomycin C or methotrexate, even at a concentration 10,000 times lower. The effect of C-1027 on pBR322 DNA suggested that the drug could cause single- or double-strand scission of DNA. As determined by flow cytometry, C-1027 delayed the progression of hepatoma cells through the S-phase and blocked the cells at G2+M. Cytological study showed that C-1027 caused a drastic reduction of the mitotic index within 1 h and that an overshot of the mitotic index occurred at 48 h. Our results indicate that C-1027 is an interesting compound with highly potent activity on cellular DNA.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2173979     DOI: 10.1007/BF00689274

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  18 in total

1.  [Antitumor activity of bleomycin A6 against human liver cancer in cell culture and in nude mice].

Authors:  M Jiang; Y S Zhen
Journal:  Yao Xue Xue Bao       Date:  1987-12

2.  Primary structure of neocarzinostatin, an antitumor protein.

Authors:  J Meienhofer; H Maeda; C B Glaser; J Czombos; K Kuromizu
Journal:  Science       Date:  1972-11-24       Impact factor: 47.728

3.  Potent antitumor antibiotic complex: PD 114,759, PD 115,028, PD 119,707, and PD 119,193.

Authors:  J B Tunac; B D Graham; S W Mamber; W E Dobson; M D Lenzini
Journal:  J Antibiot (Tokyo)       Date:  1985-10       Impact factor: 2.649

4.  A new macromolecular antitumor antibiotic, C-1027. II. Isolation and physico-chemical properties.

Authors:  T Otani; Y Minami; T Marunaka; R Zhang; M Y Xie
Journal:  J Antibiot (Tokyo)       Date:  1988-11       Impact factor: 2.649

5.  Rapid test to detect agents that damage human DNA.

Authors:  R B Painter
Journal:  Nature       Date:  1977-02-17       Impact factor: 49.962

6.  New antitumor antibiotics, FR-900405 and FR-900406. II. Production, isolation, characterization and antitumor activity.

Authors:  S Kiyoto; M Nishikawa; H Terano; M Kohsaka; H Aoki; H Imanaka; Y Kawai; I Uchida; M Hashimoto
Journal:  J Antibiot (Tokyo)       Date:  1985-07       Impact factor: 2.649

7.  Esperamicins, a novel class of potent antitumor antibiotics. I. Physico-chemical data and partial structure.

Authors:  M Konishi; H Ohkuma; K Saitoh; H Kawaguchi; J Golik; G Dubay; G Groenewold; B Krishnan; T W Doyle
Journal:  J Antibiot (Tokyo)       Date:  1985-11       Impact factor: 2.649

8.  Primary structure of macromomycin, an antitumor antibiotic protein.

Authors:  T S Samy; K S Hahm; E J Modest; G W Lampman; H T Keutmann; H Umezawa; W C Herlihy; B W Gibson; S A Carr; K Biemann
Journal:  J Biol Chem       Date:  1983-01-10       Impact factor: 5.157

9.  Purification and mechanism of action of macromomycin.

Authors:  T H Sawyer; A W Prestayko; S T Crooke
Journal:  Cancer Res       Date:  1979-04       Impact factor: 12.701

10.  Mechanism of action of macromomycin: DNA strand scission, inhibition of DNA synthesis and mitosis.

Authors:  H Suzuki; T Nishimura; K Muto; N Tanaka
Journal:  J Antibiot (Tokyo)       Date:  1978-09       Impact factor: 2.649

View more
  6 in total

1.  Inhibition of mouse embryonic carcinoma cell growth by lidamycin through down-regulation of embryonic stem cell-like genes Oct4, Sox2 and Myc.

Authors:  Hong-Ying Zhen; Qi-Hua He; Yong-Zhan Zhen; Shu-Ling Wang; Yi-Nan Liu; Wei-Hua Wu; Xiao-Yan Zhang; Ai-Li Lu; Li Shen
Journal:  Invest New Drugs       Date:  2010-07-02       Impact factor: 3.850

2.  Antitumor efficacy of lidamycin on hepatoma and active moiety of its molecule.

Authors:  Yun-Hong Huang; Bo-Yang Shang; Yong-Su Zhen
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

3.  Pharmacokinetics of C-1027 in mice as determined by TCA-RA method.

Authors:  You-Ping Liu; Quan-Sheng Li; Yu-Rong Huang; Mao-Jin Zhou; Chang-Xiao Liu
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

4.  Tissue distribution and excretion of 125I-lidamycin in mice and rats.

Authors:  You-Ping Liu; Quan-Sheng Li; Yu-Rong Huang; Chang-Xiao Liu
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

5.  Factor VII light chain-targeted lidamycin shows intensified therapeutic efficacy for liver cancer.

Authors:  Qing Zhang; Xiujun Liu; Shuangshuang Xu; Caihong Li; Yang Zhang; Jie Yang; Junnian Zheng
Journal:  Cancer Biother Radiopharm       Date:  2012-05-31       Impact factor: 3.099

6.  DNA damage by C1027 involves hydrogen atom abstraction and addition to nucleobases.

Authors:  Joanna Maria N San Pedro; Terry A Beerman; Marc M Greenberg
Journal:  Bioorg Med Chem       Date:  2012-06-09       Impact factor: 3.641

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.